Ernexa Therapeutics Inc. Gain (Loss) on Disposition of Other Assets
Ernexa Therapeutics Inc. (ERNA) reported Gain (Loss) on Disposition of Other Assets of -$13.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfOtherAssets · last filed 2026-03-13
- Ernexa Therapeutics Inc. gain (loss) on disposition of other assets for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. gain (loss) on disposition of other assets for the quarter ending 2024-06-30 was $0.00.
- Ernexa Therapeutics Inc. gain (loss) on disposition of other assets for the quarter ending 2024-03-31 was $2.00K.
- Ernexa Therapeutics Inc. gain (loss) on disposition of other assets for fiscal 2025 was -$13.00K.
| Period end | Gain (Loss) on Disposition of Other Assets 3 month | Gain (Loss) on Disposition of Other Assets 6 month | Gain (Loss) on Disposition of Other Assets 9 month | Gain (Loss) on Disposition of Other Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$13.00K 10-K · filed 2026-03-13 | ||
| 2025-09-30 | -$13.00K 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |